CN1108537A - 家庭主妇型皮炎的治疗 - Google Patents

家庭主妇型皮炎的治疗 Download PDF

Info

Publication number: CN1108537A
Authority: CN; China
Prior art keywords: sulfur; salicylic acid; dermatitis; salicylic; skin
Prior art date: 1992-09-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN94104807.1A

Other languages

English (en)

Chinese (zh)

Inventor

奥斯·沙基尔·穆斯塔法·萨利姆

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-09-04

Filing date

1994-03-16

Publication date

1995-09-20

1992-09-04 Priority to GB929218771A priority Critical patent/GB9218771D0/en

1993-09-03 Priority to AU49745/93A priority patent/AU4974593A/en

1993-09-03 Priority to PCT/GB1993/001874 priority patent/WO1994005302A1/fr

1994-03-16 Application filed by Individual filed Critical Individual

1994-03-16 Priority to CN94104807.1A priority patent/CN1108537A/zh

1995-09-20 Publication of CN1108537A publication Critical patent/CN1108537A/zh

Status Pending legal-status Critical Current

Links

201000004624 Dermatitis Diseases 0.000 title claims abstract description 27
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 58
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 32
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 29
229960004889 salicylic acid Drugs 0.000 claims abstract description 29
239000000203 mixture Substances 0.000 claims abstract description 24
230000002195 synergetic effect Effects 0.000 claims abstract description 5
230000002265 prevention Effects 0.000 claims abstract description 3
150000002148 esters Chemical class 0.000 claims abstract 6
150000003839 salts Chemical class 0.000 claims abstract 6
238000000034 method Methods 0.000 claims abstract 5
229910052717 sulfur Inorganic materials 0.000 claims description 28
239000011593 sulfur Substances 0.000 claims description 28
238000002360 preparation method Methods 0.000 claims description 19
230000003203 everyday effect Effects 0.000 claims description 10
230000000699 topical effect Effects 0.000 claims description 5
230000035479 physiological effects, processes and functions Effects 0.000 claims description 2
239000005864 Sulphur Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229940016409 methylsulfonylmethane Drugs 0.000 abstract 1
HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 abstract 1
230000000694 effects Effects 0.000 description 13
FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 10
239000002202 Polyethylene glycol Substances 0.000 description 10
229920001223 polyethylene glycol Polymers 0.000 description 10
239000006071 cream Substances 0.000 description 9
239000003814 drug Substances 0.000 description 8
239000000758 substrate Substances 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 6
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
238000005336 cracking Methods 0.000 description 4
239000003599 detergent Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
206010020751 Hypersensitivity Diseases 0.000 description 3
208000026935 allergic disease Diseases 0.000 description 3
230000007815 allergy Effects 0.000 description 3
238000001035 drying Methods 0.000 description 3
229940041616 menthol Drugs 0.000 description 3
238000011084 recovery Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
101150102923 MSM1 gene Proteins 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000000470 constituent Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
239000003921 oil Substances 0.000 description 2
239000002674 ointment Substances 0.000 description 2
238000007788 roughening Methods 0.000 description 2
238000007789 sealing Methods 0.000 description 2
230000036548 skin texture Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000008719 thickening Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
239000004382 Amylase Substances 0.000 description 1
102000013142 Amylases Human genes 0.000 description 1
108010065511 Amylases Proteins 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
206010048768 Dermatosis Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000035154 Hyperesthesia Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
208000028990 Skin injury Diseases 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000809 air pollutant Substances 0.000 description 1
231100001243 air pollutant Toxicity 0.000 description 1
235000019418 amylase Nutrition 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
-1 antiseptic Substances 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960002242 chlorocresol Drugs 0.000 description 1
239000012459 cleaning agent Substances 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000003907 kidney function Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000003908 liver function Effects 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229960001047 methyl salicylate Drugs 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
230000037311 normal skin Effects 0.000 description 1
235000014593 oils and fats Nutrition 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
LZFIOSVZIQOVFW-UHFFFAOYSA-N propyl 2-hydroxybenzoate Chemical compound CCCOC(=O)C1=CC=CC=C1O LZFIOSVZIQOVFW-UHFFFAOYSA-N 0.000 description 1
239000008213 purified water Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
230000037380 skin damage Effects 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000002689 soil Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CN94104807.1A 1992-09-04 1994-03-16 家庭主妇型皮炎的治疗 Pending CN1108537A (zh)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
GB929218771A GB9218771D0 (en)	1992-09-04	1992-09-04	Synergistic composition for dermatitis treatment
AU49745/93A AU4974593A (en)	1992-09-04	1993-09-03	Dermatitis treatment compositions containing sulphur, salicylic acid and a sulphydryl group releasing agent
PCT/GB1993/001874 WO1994005302A1 (fr)	1992-09-04	1993-09-03	Compositions de traitement de la dermite contenant du soufre, de l'acide salicylique et un agent de liberation de groupe sulfhydryle
CN94104807.1A CN1108537A (zh)	1992-09-04	1994-03-16	家庭主妇型皮炎的治疗

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB929218771A GB9218771D0 (en)	1992-09-04	1992-09-04	Synergistic composition for dermatitis treatment
CN94104807.1A CN1108537A (zh)	1992-09-04	1994-03-16	家庭主妇型皮炎的治疗

Publications (1)

Publication Number	Publication Date
CN1108537A true CN1108537A (zh)	1995-09-20

Family

ID=36954586

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN94104807.1A Pending CN1108537A (zh)	1992-09-04	1994-03-16	家庭主妇型皮炎的治疗

Country Status (4)

Country	Link
CN (1)	CN1108537A (fr)
AU (1)	AU4974593A (fr)
GB (1)	GB9218771D0 (fr)
WO (1)	WO1994005302A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5681852A (en) *	1993-11-12	1997-10-28	The Procter & Gamble Company	Desquamation compositions
US5645825A (en) *	1995-06-07	1997-07-08	The Procter & Gamble Company	Depilatory compositions comprising sulfhydryl compounds
US5821237A (en) *	1995-06-07	1998-10-13	The Procter & Gamble Company	Compositions for visually improving skin
US5683705A (en) *	1996-03-29	1997-11-04	Estee Lauder, Inc.	Sulfur-based amides and bis-amides useful against skin disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK103797C (da) *	1963-05-01	1966-02-21	Barnes Hind Lab Inc	Kosmetisk middel.
JPS58198421A (ja) *	1982-05-14	1983-11-18	Reiko Kosaka	皮膚脱色及び皮膚疾患治療用組成物
GB8517299D0 (en) *	1985-07-09	1985-08-14	Salim A S M	Dermatologically active substances

1992
- 1992-09-04 GB GB929218771A patent/GB9218771D0/en active Pending
1993
- 1993-09-03 WO PCT/GB1993/001874 patent/WO1994005302A1/fr not_active Ceased
- 1993-09-03 AU AU49745/93A patent/AU4974593A/en not_active Abandoned
1994
- 1994-03-16 CN CN94104807.1A patent/CN1108537A/zh active Pending

Also Published As

Publication number	Publication date
AU4974593A (en)	1994-03-29
WO1994005302A1 (fr)	1994-03-17
GB9218771D0 (en)	1992-10-21

Legal Events

Date	Code	Title
1995-09-20	C06	Publication
1995-09-20	PB01	Publication
1998-07-08	C01	Deemed withdrawal of patent application (patent law 1993)
1998-07-08	WD01	Invention patent application deemed withdrawn after publication

Publication	Publication Date	Title
KR100347651B1 (ko)	2002-11-30	단순포진바이러스및다른감염성질병의치료를위한항균성조성물
CN1108527A (zh)	1995-09-20	用于头发再生的协同组合物
CA2408541C (fr)	2009-07-28	Traitement contre l'eczema et/ou le psoriasis
US6613800B1 (en)	2003-09-02	Method and compositions for treating psoriasis, eczema, seborrhea and arthritis
AU2001260833A1 (en)	2002-02-07	Treating eczema and/or psoriasis
JPH08505388A (ja)	1996-06-11	ヒアルロン酸−尿素医薬組成物およびその使用
CA2255681C (fr)	2009-02-10	Composition et procede de traitement de l'herpes simplex
US8586064B2 (en)	2013-11-19	Treating eczema and/or psoriasis
CN1108537A (zh)	1995-09-20	家庭主妇型皮炎的治疗
US20060205699A1 (en)	2006-09-14	Topical treatment for psoriasis
CN1055392C (zh)	2000-08-16	治疗牛皮癣的药物组合物及其药用
GB2177918A (en)	1987-02-04	Pharmaceutical compositions containing procaine
CN107050060A (zh)	2017-08-18	治疗牛皮癣的外用药及药物组合物
CN1393221A (zh)	2003-01-29	一种治疗痤疮的药液
WO1994005301A1 (fr)	1994-03-17	Compositions destinees au traitement de la dermite, contenant du soufre, de l'acide salicylique et du dimethylsulfone
CN1108538A (zh)	1995-09-20	治疗皮炎的协同作用组合物
RU2171682C1 (ru)	2001-08-10	Мазь для лечения псориаза
CN100558363C (zh)	2009-11-11	一种治疗尖锐湿疣的药物组合物
US6395779B1 (en)	2002-05-28	Method of treatment using peroxidized lipids
Semon	2013	An Atlas of the Commoner Skin Diseases: With 147 Plates Reproduced by Direct Colour Photography from the Living Subject
SU1395328A1 (ru)	1988-05-15	Способ лечени диффузного нейродермита
SIMPSON et al.	1940	Vitamin D in the treatment of acne
FI119101B (fi)	2008-07-31	Magnesiumsuoloja sisältävä hoitoaine kasvainten tai vastaavien hoitoon ja magnesiumsulfaatin käyttö
EP2192912B1 (fr)	2016-06-01	Huile essentielle de kunzea ambigua et procédés d'utilisation
EP2849742A1 (fr)	2015-03-25	Procédé de traitement topique de la kératose actinique avec un traitement cyclique au mébutate d'ingénol